Ecoza Topical and Methadone Hydrochloride

• Generic Name: econazole topical
• Dosage Forms: aerosol, foam
• Other Brand Names: Econazole Nitrate, Ecoza, Spectazole

Econazole topical is used to treat infections caused by a fungus or yeast. It works by killing the fungus or yeast or preventing its growth.

Econazole cream is used to treat:

• Ringworm of the body (tinea corporis);
• Ringworm of the foot (tinea pedis; athlete's foot);
• Ringworm of the groin (tinea cruris; jock itch);
• Sun fungus (tinea versicolor); and
• Yeast infection of the skin (cutaneous candidiasis).

Econazole foam is used to treat ringworm of the foot between the toes (interdigital tinea pedis; athlete's foot).

This medicine is available only with your doctor's prescription.

• Generic Name: methadone
• Dosage Forms: n.a.
• Other Brand Names: Dolophine, Methadose, Methadose Sugar-Free, Diskets

Used parenterally for the relief of moderate to severe pain that has not responded to nonopiate analgesics.

Used orally for the relief of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. Oral preparations are not indicated for relief of acute (e.g., postoperative) pain, for relief of pain that is mild or is not expected to persist for an extended period of time, or for use on an as-needed (“prn”) basis.

For relief of chronic pain in both opiate-naive patients and in individuals being switched to methadone therapy from other opiate agonists because of inadequate pain relief or adverse effects from the previous drug (opiate rotation).

Clinical studies suggest that efficacy may be similar to that of morphine and other opiates in patients with chronic malignant pain. However, experts generally agree that methadone should be prescribed for chronic pain management only by clinicians knowledgeable about its risks (e.g., QT-interval prolongation) and pharmacokinetics, and should not be the first choice for an extended-release or long-acting opiate analgesic.

Benefits associated with use of methadone for management of chronic pain include the commercial availability of multiple dosage forms of the drug, good oral bioavailability, rapid onset of action, reduced dosing frequency (because of the drug’s long half-life), low cost, and lack of active metabolites.

Disadvantages associated with use include increased potential for accumulation with repeated doses (which may result in toxicity), considerable interindividual variability in pharmacokinetic parameters, potential for drug interactions, challenges associated with dosage titration and with the transfer of patients from therapy with other opiate agonists, and commercial availability and relative ease of use of extended-release preparations of other opiate agonists.

Generally use opiates for management of chronic pain (i.e., pain lasting >3 months or past the time of normal tissue healing ) that is not associated with active cancer treatment, palliative care, or end-of-life care only if other appropriate nonpharmacologic and nonopiate pharmacologic strategies have been ineffective and expected benefits for both pain relief and functional improvement are anticipated to outweigh risks.

If used for chronic pain, opiate analgesics should be part of an integrated approach that also includes appropriate nonpharmacologic modalities (e.g., cognitive-behavioral therapy, relaxation techniques, biofeedback, functional restoration, exercise therapy, certain interventional procedures) and other appropriate pharmacologic therapies (e.g., nonopiate analgesics, analgesic adjuncts such as selected anticonvulsants and antidepressants for certain neuropathic pain conditions).

Available evidence insufficient to determine whether long-term opiate therapy for chronic pain results in sustained pain relief or improvements in function and quality of life or is superior to other pharmacologic or nonpharmacologic treatments. Use is associated with serious risks (e.g., opiate use disorder, overdose). (See Managing Opiate Therapy for Chronic Noncancer Pain under Dosage and Administration.)

Used in detoxification treatment and maintenance treatment as an oral substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

Success of treatment is dependent on the selection of properly motivated patients and on availability of social, psychologic, vocational, and educational as well as medical supportive services.

Has been used to manage manifestations of opiate abstinence syndrome (i.e., postnatal withdrawal) in neonates exposed to opiates in utero.

Opiates recommended as first-line pharmacologic therapy when environmental and supportive measures (e.g., minimization of external stimuli, maximization of mother-infant contact [e.g., parental “rooming in”], breast-feeding when not contraindicated, swaddling and gentle handling) are inadequate. May add other adjunctive therapy (e.g., clonidine, phenobarbital) if response to opiates is inadequate or add phenobarbital if neonate was exposed to additional substances in utero.

While morphine has been used more extensively than other opiates in the management of neonatal opiate abstinence syndrome, some studies suggest methadone or buprenorphine may be associated with shorter treatment durations and hospital stays. Additional study needed to establish optimal dosage schedules and preferred opiate drugs and to evaluate longer-term (e.g., neurodevelopmental) outcomes.

Use of standardized protocols for identification, evaluation, and treatment recommended; use of protocols improves overall response, including shorter hospital stays and durations of pharmacologic treatment. Some evidence suggests that use of a standardized protocol may be more important than use of a specific opiate agonist (e.g., methadone versus morphine) in improving outcomes.